Paper35740211
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.
Rattanaumpawan P and 4 others. Antibiotics (Basel), 2022. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. Papers, record 35740211. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35740211
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R016333038 | Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand | PubMed |
Source PubMed
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28231247 | Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. | PLoS Negl Trop Dis | 2017 | https://conductscience.org/library/papers/28231247 | PubMed |
| 2 | 31822885 | Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. | J Infect Dis | 2020 | https://conductscience.org/library/papers/31822885 | PubMed |
| 3 | 32346491 | Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. | Engineering (Beijing) | 2020 | https://conductscience.org/library/papers/32346491 | PubMed |
| 4 | 35470021 | The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. | Int J Infect Dis | 2022 | https://conductscience.org/library/papers/35470021 | PubMed |
| 5 | 32958718 | A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32958718 | PubMed |
| 6 | 31986264 | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. | Lancet | 2020 | https://conductscience.org/library/papers/31986264 | PubMed |
| 7 | 34750163 | Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. | BMJ | 2021 | https://conductscience.org/library/papers/34750163 | PubMed |
| 8 | 28769016 | Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. | Proc Jpn Acad Ser B Phys Biol Sci | 2017 | https://conductscience.org/library/papers/28769016 | PubMed |
| 9 | 35026375 | Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. | Clin Microbiol Infect | 2022 | https://conductscience.org/library/papers/35026375 | PubMed |
| 10 | 34849615 | Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/34849615 | PubMed |
| 11 | 33930706 | Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/33930706 | PubMed |
| 12 | 33212256 | Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. | Int J Infect Dis | 2021 | https://conductscience.org/library/papers/33212256 | PubMed |
| 13 | 32250385 | Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. | JAMA | 2020 | https://conductscience.org/library/papers/32250385 | PubMed |
| 14 | 27553371 | Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/27553371 | PubMed |
| 15 | 35535140 | Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting. | Int J Gen Med | 2022 | https://conductscience.org/library/papers/35535140 | PubMed |
| 16 | 32423584 | Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. | Lancet | 2020 | https://conductscience.org/library/papers/32423584 | PubMed |
| 17 | 34539392 | Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34539392 | PubMed |
| 18 | 34937145 | Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34937145 | PubMed |
| 19 | 32302078 | Clinical Characteristics of Covid-19 in New York City. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32302078 | PubMed |
| 20 | 34941423 | A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/34941423 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40465794 | In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand. | PLoS One | 2025 | https://conductscience.org/library/papers/40465794 | PubMed |
| 40420912 | Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40420912 | PubMed |
| 39509583 | Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure. | Pharmacol Res Perspect | 2024 | https://conductscience.org/library/papers/39509583 | PubMed |
| 38770366 | Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study. | Int J Gen Med | 2024 | https://conductscience.org/library/papers/38770366 | PubMed |
| 38493271 | Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19. | Inflammopharmacology | 2024 | https://conductscience.org/library/papers/38493271 | PubMed |
| 37689754 | Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV). | Sci Rep | 2023 | https://conductscience.org/library/papers/37689754 | PubMed |
| 37374302 | The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study. | Medicina (Kaunas) | 2023 | https://conductscience.org/library/papers/37374302 | PubMed |
| 36776761 | Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand. | Lancet Reg Health Southeast Asia | 2023 | https://conductscience.org/library/papers/36776761 | PubMed |
| 36678542 | Favipiravir-Tautomeric and Complexation Properties in Solution. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36678542 | PubMed |
| 36661514 | A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/36661514 | PubMed |
| 36603821 | An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand. | Infect Chemother | 2023 | https://conductscience.org/library/papers/36603821 | PubMed |
| 36521656 | COVID-19 signalome: Potential therapeutic interventions. | Cell Signal | 2023 | https://conductscience.org/library/papers/36521656 | PubMed |
| 36160358 | Perspective: repurposed drugs for COVID-19. | Arch Med Sci | 2022 | https://conductscience.org/library/papers/36160358 | PubMed |
| 35685498 | Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel. | Int J Clin Pract | 2022 | https://conductscience.org/library/papers/35685498 | PubMed |
| 35543795 | Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19? | Geroscience | 2022 | https://conductscience.org/library/papers/35543795 | PubMed |
| 35535140 | Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting. | Int J Gen Med | 2022 | https://conductscience.org/library/papers/35535140 | PubMed |
| 35470021 | The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. | Int J Infect Dis | 2022 | https://conductscience.org/library/papers/35470021 | PubMed |
| 35214034 | Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35214034 | PubMed |
| 34548811 | Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. | Int J Gen Med | 2021 | https://conductscience.org/library/papers/34548811 | PubMed |
| 33526596 | Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/33526596 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35740211
GET https://conductscience.org/api/papers/v1/35740211/references?page=2